Gavi alliance jpg

GAVI, the Vaccine Alliance


  • Organization TypeFunding Agencies
  • Staff101-250
  • Development BudgetOver 500 Million
  • HeadquartersSwitzerland
  • Founded2000
Gavi, the Vaccine Alliance is a public-private global health partnership, created in 2000 to bring together public and private sectors with the shared goal of creating equal access to new and underused vaccines for children living in the world’s poorest countries. Partners include developing country and donor governments, WHO, UNICEF, the World Bank, the vaccine industry in both industrialised and developing countries, research and technical agencies, civil society organisations, the Bill & Melinda Gates Foundation and other private philanthropists. WHO estimates that, in Gavi’s first decade, Gavi support has contributed to the immunisation of an additional 440 million children. The Alliance is supported by a small Secretariat based in Geneva and Washington, DC. MEMBERS OF THE GAVI ALLIANCE   The Bill & Melinda Gates Foundation Civil Society Organisations Developing Country Governments Donor Country Governments Research And Technical Health Institutes Unaffiliated Board Members UNICEF The Vaccine Industry from the developing countries and industrialised countries WHO The World Bank Group SUPPORT COUNTRIES CAN APPLY FOR   new and underused vaccines support; health system strengthening support; support to civil society involvement in immunisation planning and delivery; immunisation services support (performance-based cash support) and injection safety support. COUNTRIES ELIGIBLE FOR GAVI SUPPORT Gavi aims to focus on the world’s poorest countries. Eligibility is therefore determined by national income with all countries with a Gross National Income (GNI) per capita below or equal to US$1,570 (according to Wold Bank data for the latest available year) qualifying for support. There are currently 53 Gavi-eligible countries. However, not all of these countries qualify for every type of support because Gavi sets conditions for each type of support. Support is provided in response to country proposals, which are reviewed by an independent group of experts – mostly health officials from developing countries. Gavi support is available to the 73 poorest countries in the world. By the end of 2013, 22 countries were projected to graduate from Gavi’s support by 2020. STRATEGY 2016-2020 Gavi’s Board has approved a revised five-year strategy to continue to build sustainable programmes and deliver on its mission to save children’s lives and protect people’s health by increasing equitable use of vaccines in lower income countries. The revised five-year strategy (2016-2020), approved by the Gavi Board on 19 June 2014, builds on the current strategy and draws lessons from the previous 15 years. The strategy is designed to adapt to the changing environment in which the Vaccine Alliance and the countries it is supporting will operate The 2016-20 strategy has four goals, each supporting Gavi’s overall mission: “to save children’s lives and protect people’s health by increasing equitable use of vaccines in lower income countries.” Accelerate equitable uptake and coverage of vaccines. Increase effectiveness and efficiency of immunisation delivery as an integrated part of strengthened health systems. Improve sustainability of national immunisation programmes. Shape markets for vaccines and other immunisation products.   The strategic framework includes eight principles, intended to define the Vaccine Alliance’s characteristics, its business model and its aspirations: country-led, community-owned, globally engaged, catalytic and sustainable, integrated, innovative, collaborative and accountable. Vaccines have a long-term positive impact beyond health outcomes. Expanded immunisation in Gavi-supported countries from 2016 to 2020 could deliver more than 100 million illness cases averted. This will reduce the burden of care on parents, improving their productivity and freeing them from crippling medical costs. And by protecting children from infectious diseases, vaccines will also help raise IQ levels. Renewed investment from donors, together with co-financing from recipient countries and support from vaccine manufacturers, will help immunise an additional 300 million children from 2016-2020. This will result in 5-6 million lives saved and economic benefits of US$ 80-100 billion GAVI’S ACHIEVEMENTS SO FAR   Since its launch in 2000, Gavi has helped developing countries to prevent 6 million future deaths from hepatitis B, Haemophilus influenzae type b (Hib), measles, meningitis A, pneumococcal disease, rotavirus diarrhoea and yellow fever. Immunisation coverage for three doses of the diphtheria-tetanus-pertussis vaccine (DTP3) reached 76% in 2013 in the 73 countries supported by the Alliance. Through the Advance Market Commitment, pneumococcal vaccines are available to GAVI-eligible countries at no more than US$ 3.50 per dose, a more than 90% reduction compared with the public price in the United States. In 2013, Gavi secured a lowest price offer for pneumococcal vaccines of US$ 3.30 per dose from 2014 onwards. Gavi works with manufacturers to bring down HPV prices. In 2013, a new price of US$ 4.50 per dose was agreed, a two-thirds reduction on the current lowest public price. Through a catalytic programme of support, GAVI has helped set new standards for injection safety.  

Where is GAVI, the Vaccine Alliance
Staff8Location of current staff
    Location of open jobs
    Projects3Location of contracts awarded


    Job openings over the past year

    71total posted jobs

    Examples of past jobs

    • Senior Manager, North American Communication
      United States
    • Senior Manager, Investments
      United States

    Staff at GAVI, the Vaccine Alliance have experience in


    • reproductive health
    • infectious disease
    • development
    • market research
    • monitoring / evaluation


    • united states agency for international development
    • department for international development
    • foundation
    • centers for disease control and prevention
    • bill & melinda gates foundation


    • india
    • nigeria
    • south africa
    • malawi
    • south sudan


    • managerial experience
    • business development
    • experience in recruitment
    • international experience
    • with experience in conflict areas

    Contact GAVI, the Vaccine Alliance

    Current staff

    {{contact.full_name}} - {{contact.headline || contact.employment_title}}
    • Anna Schneider
      Analyst, Innovative Finance & Private Sector Partnerships
      +1 202 478 7981
    • Updated {{contact.updated_at | date:dateFormat}}

    Former staff

    {{contact.full_name}} - {{contact.headline || contact.employment_title}}
    • Updated {{contact.updated_at | date:dateFormat}}
    Company Offices
    • Switzerland (headquarters)
    • Geneva
    • 2 Chemin des Mines
    • United States
    • Washington, DC
    • 1776 I (Eye) Street, NW Suite 600


    Primary sectors

    Infectious Disease
    Private Sector Development
    Banking & Finance Budgeting
    Reproductive Health
    Market Research
    Public Administration
    Events / Training
    Monitoring / Evaluation
    Project Design

    Contract Awards

    Support to Gavi, the Vaccine Alliance – 2016-202029 April 2016

    Department of Foreign Affairs, Trade and Development (Canada) - DFATD-Canada
    29 Apr 2016

    Introducing Pneumococcal Vaccines in Least Developed ACP Countries2 July 2011

    EuropeAid Co-operation Office - EuropeAID
    2 Jul 2011

    Core payment to GAVI - 201030 June 2011

    Australian Agency for International Development - AusAID
    30 Jun 2011